Skip to main content

Advertisement

SpringerLink
Log in

C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease

  • Original Article—Alimentary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

The ability of serum infliximab level to predict clinical outcome in infliximab therapy in Crohn’s disease is unclear. Here, we aimed to clarify the correlation between the timing of loss of response (LOR) to treatment and a decrease in serum infliximab level, and, in addition, to identify an indicator of infliximab level.

Methods

The study used data from a previous clinical study of infliximab for Crohn’s disease, in which infliximab was initially given at 0, 2, 6 weeks at 5 mg/kg, and then at 8-week intervals to 62 week-10 responders. Of these 62, here we analysed data from 57 in whom Crohn’s disease activity index and serum infliximab level were evaluated at week 14.

Results

Twelve patients showed a clinical response despite an infliximab level <1 μg/mL at week 14; of these, 8 (67 %) experienced LOR by week 54. A decrease in infliximab level preceded LOR in 6 (75 %). In receiver operating characteristic curve analysis, C-reactive protein (CRP) showed better performance in detecting an infliximab level <1 μg/mL. Infliximab level was <1 μg/mL in 60–80 % of patients with CRP >0.5 mg/dL. Time to LOR (median: 22.0 weeks) was significantly longer than that to a decrease in infliximab level to <1 μg/mL (14.0 weeks, p < 0.05) or to an increase in CRP to >0.5 mg/dL (14.0 weeks, p < 0.01).

Conclusions

A decrease in serum infliximab level preceded LOR, and was easily detected by an increase in CRP. The CRP may be an indicator of serum infliximab level in predicting LOR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Peyrin-Biroulet L, Loftus EV Jr, Colombel J-F, Sandborn WJ. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2010;105:289–97.

    Article  PubMed  Google Scholar 

  2. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med. 1997;337:1029–35.

    Article  CAS  PubMed  Google Scholar 

  3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.

    Article  CAS  PubMed  Google Scholar 

  4. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–7.

    Article  CAS  PubMed  Google Scholar 

  5. Allez M, Karmiris K, Louis E, Assche GV, Ben-Horin S, Klein A, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4:355–66.

    Article  PubMed  Google Scholar 

  6. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn’s disease: a user’s guide for clinicians. Am J Gastroenterol. 2002;97:2962–72.

    Article  CAS  PubMed  Google Scholar 

  7. Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, et al. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn’s disease. Inflamm Bowel Dis. 2012;18:1480–7.

    Article  PubMed  Google Scholar 

  8. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552–63.

    Article  CAS  PubMed  Google Scholar 

  9. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:1248–54.

    Article  CAS  PubMed  Google Scholar 

  10. Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133–9.

    Article  CAS  PubMed  Google Scholar 

  11. Guerra I, Chaparro M, Bermejo F, Gisbert JP. Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease. Curr Drug Metab. 2011;12:594–8.

    Article  CAS  PubMed  Google Scholar 

  12. Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390–407.

    Article  CAS  PubMed  Google Scholar 

  13. Louis E, Belaiche J, van Kemseke C, Franchimont D, de Groote D, Gueenen V, et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn’s disease. Eur J Gastroenterol Hepatol. 1997;9:939–44.

    Article  CAS  PubMed  Google Scholar 

  14. Song L, Hanlon DW, Chang L, Provuncher GK, Kan CW, Campbell TG, et al. Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn’s disease. J Immunol Methods. 2011;372:177–86.

    Article  CAS  PubMed  Google Scholar 

  15. Kato K, Fukunaga K, Kamikozuru K, Kashiwamura S, Hida N, Ohda Y, et al. Infliximab therapy impacts the peripheral immune system of immunomodulator and corticosteroid naïve patients with Crohn’s disease. Gut Liver. 2011;5:37–45.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol. 1999;163:1521–8.

    CAS  PubMed  Google Scholar 

  17. Knudsen LS, Ostergaard M, Baslund B, Narvestad E, Petersen J, Nielsen HJ, et al. Plasma IL-6, plasma VEGF, and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate. Scand J Rheumatol. 2006;35:489–91.

    Article  CAS  PubMed  Google Scholar 

  18. Dain L, Braun-Moscovici Y, Baum E, Nahir AM, Hoffer E. Modification of neutrophil function by plasma of rheumatoid arthritis patients treated with infliximab. Clin Exp Rheumatol. 2006;24:38–44.

    CAS  PubMed  Google Scholar 

  19. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–31.

    Article  CAS  PubMed  Google Scholar 

  20. Jürgens M, Mahachie John JM, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2011;9:421–7.

    Article  PubMed  Google Scholar 

  21. Reinisch W, Wang Y, Oddens BJ, Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn’s disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568–76.

    Article  CAS  PubMed  Google Scholar 

  22. Kiss LS, Papp M, Lovasz BD, Vegh Z, Golovics PA, Janka E, et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn’s disease: a marker for patient classification? Inflamm Bowel Dis. 2012;18:1647–54.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was sponsored by Mitsubishi Tanabe Pharma Corporation. The authors thank the patients, investigators, and study personnel who made the trial possible. We also thank the following investigators for their involvement: Noriaki Watanabe (Department of Internal Medicine, Kitasato Institute Hospital, Tokyo, Japan), Tomoe Katsumata (Department of Gastroenterology, Kitasato University East Hospital, Sagamihara, Japan), Hidemi Goto (Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan), Akiyoshi Nishio (Department of Gastroenterological Endoscopy, Kyoto University Hospital, Kyoto, Japan).

Conflict of interest

T. Hibi has received grant/research support from Ajinomoto Pharmaceuticals, JIMRO, and Mitsubishi Tanabe Pharma. M. Watanabe has received grant/research support and lecture fees from Abbott Japan, Ajinomoto Pharmaceuticals, Asahi Kasei Medical, Astellas Pharma, AstraZeneca, Chugai Pharmaceutical, DAIICHI SANKYO, Eisai, JIMRO, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, UCB Japan, and Zeria Pharmaceutical. H. Ito has received lecture fees from Mitsubishi Tanabe Pharma. N. Sato and T. Yoshinari are employees of Mitsubishi Tanabe Pharma. Y. Suzuki has received lecture fees from Mitsubishi Tanabe Pharma. T. Matsumoto has received grant/research support from Asahi Kasei Medical, Ajinomoto Pharmaceuticals, Astellas Pharma, Eisai, EN Otsuka Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Otsuka Pharmaceutical Factory, UCB Japan, and Zeria Pharmaceutical. The other authors have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

    Toshifumi Hibi & Atsushi Sakuraba

  2. Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan

    Mamoru Watanabe

  3. Inflammatory Bowel Diseases Center, Sapporo-Kosei General Hospital, Sapporo, Japan

    Satoshi Motoya

  4. Kinshukai Infusion Clinic, Osaka, Japan

    Hiroaki Ito

  5. Mitsubishi Tanabe Pharma Corporation, Osaka, Japan

    Noriko Sato & Toru Yoshinari

  6. Department of Gastroenterology, Gunma Prefectural Cancer Center, Ota, Japan

    Kenta Motegi

  7. Health Administration Center, Center for the Advancement of Higher Education, Tohoku University Graduate School of Medicine, Sendai, Japan

    Yoshitaka Kinouchi

  8. Inflammatory Bowel Diseases Center, Social Insurance Central General Hospital, Tokyo, Japan

    Masakazu Takazoe

  9. Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan

    Yasuo Suzuki

  10. Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Takayuki Matsumoto

  11. Matsuda Hospital Colo-Proctological Institute, Hamamatsu, Japan

    Kazuhiko Kawakami

  12. Department of Lower Gastroenterology, Hyogo College of Medicine, Nishinomiya, Japan

    Takayuki Matsumoto

  13. Department of Gastroenterology, Fujita Health University, Toyoake, Japan

    Ichiro Hirata

  14. Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan

    Shinji Tanaka

  15. The Third Department of Internal Medicine, Asahikawa Medical College, Asahikawa, Japan

    Toshifumi Ashida

  16. Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan

    Toshiyuki Matsui

Authors
  1. Toshifumi Hibi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atsushi Sakuraba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mamoru Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Satoshi Motoya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroaki Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Noriko Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toru Yoshinari
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kenta Motegi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshitaka Kinouchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masakazu Takazoe
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yasuo Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Takayuki Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kazuhiko Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Takayuki Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ichiro Hirata
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Shinji Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Toshifumi Ashida
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Toshiyuki Matsui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshifumi Hibi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hibi, T., Sakuraba, A., Watanabe, M. et al. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease. J Gastroenterol 49, 254–262 (2014). https://doi.org/10.1007/s00535-013-0807-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-013-0807-0

Keywords

Search

Navigation